These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8378539)

  • 21. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
    Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
    Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
    Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
    Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
    Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
    Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
    Hardee MM; Moore JN; Hardee GE
    Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man.
    MacNab MW; Foltz EL; Graves BS; Rinehart RK; Tripp SL; Feliciano NR; Sen S
    J Clin Pharmacol; 1984; 24(2-3):76-83. PubMed ID: 6371062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma.
    Orchard MA; Waddell KA; Lewis PJ; Blair IA
    Thromb Res; 1985 Sep; 39(6):701-10. PubMed ID: 3936223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
    Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
    Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat.
    Cook HT; Cattell V; Smith J; Salmon JA; Moncada S
    Clin Nephrol; 1986 Oct; 26(4):195-202. PubMed ID: 3490944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ethanol on thromboxane and prostacyclin synthesis by fetal platelets and umbilical artery.
    Ylikorkala O; Halmesmäki E; Viinikka L
    Life Sci; 1987 Jul; 41(3):371-6. PubMed ID: 3110528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.
    Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C
    J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aprotinin decreases release of 6-keto-prostaglandin F1 alpha and increases release of thromboxane B2 in cultured human umbilical vein endothelial cells.
    Havel MP; Griesmacher A; Weigel G; Owen A; Simon P; Müller MM; Wolner E
    J Thorac Cardiovasc Surg; 1992 Sep; 104(3):654-8. PubMed ID: 1381028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
    Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
    J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of angiotensin-converting enzyme inhibitors on glomerular eicosanoid production in normotensive and spontaneously hypertensive rats.
    Harding P; Stonier C; Aber GM
    Clin Sci (Lond); 1991 Oct; 81(4):491-7. PubMed ID: 1657495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arachidonic acid metabolites produced by platelet-depleted human blood monocytes: a possible role in thrombogenesis.
    Jones CM; Hall ER; Hester JP; Wu KK
    Am J Hematol; 1989 Jul; 31(3):145-52. PubMed ID: 2741910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasoactive mediators in pregnancy-induced hypertensive disorders: a longitudinal study.
    Paarlberg KM; de Jong CL; van Geijn HP; van Kamp GJ; Heinen AG; Dekker GA
    Am J Obstet Gynecol; 1998 Dec; 179(6 Pt 1):1559-64. PubMed ID: 9855596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of fenflumizole on aggregation ex vivo of human platelets and formation of thromboxane B2 and 6-keto-prostaglandin-F1 alpha.
    Vinge E; Corell T; Andersson KE
    Eur J Clin Pharmacol; 1984; 26(6):711-7. PubMed ID: 6436029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man.
    Fischer S; Struppler M; Böhlig B; Bernutz C; Wober W; Weber PC
    Circulation; 1983 Oct; 68(4):821-6. PubMed ID: 6352080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.